Heptares Therapeutics, a subsidiary of Tokyo-based Sosei, has licensed its migraine treatment candidates to Teva Pharmaceutical Industries (NYSE:TEVA).
The heavy hitters from the pharmaceuticals sector have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.
Heptares will receive an advance payment of US$10mln, and is eligible to receive milestone payments of up to US$400mln, on top of which it will be in line for royalties on net sales of produces resulting from the collaboration.
“CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody,” said Dr Michael Hayden, president of Global Research & Development and the chief scientific officer at Teva.
Malcolm Weir, chief executive officer of Heptares, said: “Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.”